Short-acting tryptamine; GH Research Phase 2b (2025) showed -15.5 MADRS vs placebo in TRD.
5-MeO-DMT is a tryptamine psychedelic structurally related to, but pharmacologically distinct from, the N,N-DMT found in ayahuasca. Unlike N,N-DMT, which is a relatively selective 5-HT2A agonist, 5-MeO-DMT is a non-selective serotonin agonist with particularly high affinity for the 5-HT1A receptor subtype — a different mechanism, and one researchers suspect underlies its distinct subjective profile.2
The compound occurs naturally in the venom of the Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) and in several plant species. Most current clinical use relies on synthetic material; conservation and welfare concerns have pushed responsible practitioners away from toad-derived preparations.
The pharmacokinetics are what set 5-MeO-DMT apart:
The short duration is clinically attractive: a dose-and-discharge paradigm is feasible. In GH Research’s Phase 2b trial, 97.4% of patients were ready to be discharged within an hour of their last dose, with no post-discharge restrictions required.1
Published in JAMA Psychiatry in 2025, the GH001 TRD-201 trial (NCT05800860) is the most rigorous 5-MeO-DMT dataset to date.2
| Parameter | GH001 arm (n=40) | Placebo arm (n=41) |
|---|---|---|
| MADRS change from baseline, Day 8 | -15.2 points | +0.3 points |
| Placebo-adjusted difference | -15.5 points (p<0.0001) | |
| Remission at Day 8 (MADRS ≤10) | 57.5% | 0% |
| Response at Day 8 | 60.0% | 0% |
| Serious adverse events (double-blind period) | 0 | 0 |
The trial design used an individualized dosing regimen (IDR): up to three escalating doses (6 mg, 12 mg, 18 mg) on a single day, with psychological support but no planned psychotherapy — an important difference from psilocybin and MDMA protocols. This framing treats 5-MeO-DMT more like an anesthetic or a drug than a drug-plus-therapy intervention.
In the open-label extension phase, 73% of completers were in remission at 6 months, and most (63%) needed only 1–4 re-treatments to maintain that remission.2 Durability of this magnitude, with such infrequent dosing, is genuinely novel.
The Phase 2b trial reported:
5-MeO-DMT is Schedule I in the United States — possession and distribution carry felony penalties. Clinical research occurs under FDA Investigational New Drug (IND) authorization.
GH Research’s US development of GH001 was under FDA clinical hold for part of 2023–2025; the hold was lifted in early 2026, and the company has signaled a global Phase 3 program. If that program succeeds, GH001 would likely become the first 5-MeO-DMT product to face an NDA review.
Internationally, 5-MeO-DMT is scheduled in most countries but unscheduled in a few jurisdictions, where retreat-based access has emerged. Mexico and Costa Rica are the most common destinations for English-speaking retreat-goers. As with ayahuasca, regulatory frameworks in those countries are substantially lighter than the safeguards in clinical trials.
Clinical trials. GH Research (NCT05800860 and planned Phase 3 successors), and a small number of academic studies — check ClinicalTrials.gov. Selection is competitive and most trials enroll treatment-resistant depression specifically.
International retreats. Safer operators publish their medical screening criteria, require medication disclosure, have medical staff on site, and do not combine 5-MeO-DMT with other psychedelics in a single session. Operators offering "toad medicine" as part of a longer multi-substance retreat carry meaningfully higher risk.
What to avoid. Any setting that does not ask about serotonergic medications, cardiovascular history, or personal/family psychosis history. Claims that 5-MeO-DMT treats depression, addiction, or trauma without clinical infrastructure. Combination with MAOIs, kambo, ayahuasca, or SSRIs in the same day.
Unlike psilocybin, MDMA, or ketamine protocols, the GH001 trial deliberately omitted structured psychotherapy — a signal that the drug’s benefit may not require the same preparation scaffolding. That said, ego-dissolution experiences of this magnitude typically require integration support afterward, particularly for people with trauma history. See the integration therapy guide.